Inhibitory effects of anti-immunoglobulin E antibodies on airway remodeling in a murine model of chronic asthma

Journal of Asthma

Volumn 47, Issue 4, 2010, Pages 374-380

  Kang, Ji Young ^a   Kim, Jin Woo ^a   Kim, Ju Sang ^a   Kim, Seung Joon ^a   Lee, Sang Haak ^a   Kwon, Soon Suk ^a   Kim, Young Kyoon ^a   Moon, Hwa Sik ^a   Song, Jeong Sup ^a   Park, Sung Hak ^a   Lee, Sook Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Airway remodeling; Asthma; Immunoglobulin E; Monoclonal antibody

Indexed keywords

ACTIVIN A; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; HYDROXYPROLINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; METHACHOLINE; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; EOSINOPHIL; FEMALE; LUNG LAVAGE; MOUSE; NONHUMAN; PROVOCATION TEST; RESPIRATORY TRACT INFLAMMATION; TH2 CELL;

ACTINS; AIRWAY REMODELING; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; COLLAGEN; CYTOKINES; EOSINOPHILS; FEMALE; HYDROXYPROLINE; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; OVALBUMIN;

EID: 77953334914     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770901003801972     Document Type: Article

References (36)

1. Boulet LP, Sterk PJ. Airway remodeling: the future. Eur Respir J 2007; 30:831-834.
2. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116:477-486.
3. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008; 121:560-570.
4. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164:s6-s11.
5. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:s12-s17.
6. Djukanovíc R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
7. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Rodriguez M, et al. Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am J Respir Cell Mol Biol 2004; 30:651-661.
8. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Broide DH. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004; 113:551-560.
9. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Raz E, Broide DH. Immuostimulatory DNA reverses established allergen induced airway remodeling. J Immunol 2004; 173:7556-7564.
10. Rhee CK, Lee SY, Kang JY, Kim SJ, Kwon SS, Kim YK, Park SH. Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol 2009; 148:289-296.
11. Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994; 82:306-313.
12. Colye AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophilic infiltration and T helper 2 cell cytokine production: inhibition by a nonanaphlyactogenic anti-IgE antibody. J Exp Med 1996; 183:1303-1310.
13. Halle S, Lefort J, Eum SY, Dumarey C, Huerre M, Heusser C, Vargaftig BB. Suppression of immediate and late response to antigen by a nonanaphylactogenic anti-IgE antibody in a murine model of asthma. Eur Respir J 1999; 13:961-969.
14. Tumas DB, Chan B, Werther W, Wrin T, Vennari J, Desjardin N, Shields RL, Jardieu P. Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization. J Allergy Clin Immunol 2001; 107:1025-1033.
15. Kumar RK, Foster PS. Murine model of chronic human asthma. Immunol Cell Biol 2001; 79:141-144.
16. Schoenhoff M, Bates D, Ruppel J, Fei D, Fox JA, Thomas D, Jardieu P. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti-IgE antibody in cynomolgus monkeys. J Allergy Clin Immunol 1995; 95:356.
17. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK,Watrous ML, Metzqer WJ. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Eng J Med 1999; 341:1966-1973.
18. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
19. Steiss JO, Strohner P, Zimmer KP, Lindermann H. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008; 45: 233-236.
20. Fick RB Jr, Fox JA, Jardieu PM. Immunotherapy approach to allergic disease. Immunotherapy approach to allergic disease. Immunopharmacology 2000; 48: 307-310.
21. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001; 126:97-101.
22. Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol 2004; 113:1204-1210.
23. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-2260.
24. Wills-KarpM. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001; 107:9-18.
25. Fahy JV. Anti-IgE: lesson learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006; 117:1230-1232.
26. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131:46-52.
27. van Rensen EL, Evertse CE, van SchadewijkWA, vanWijingaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009; 64:72-80.
28. Strunk RC, Blooming GR. Omalizumab for asthma. N Engl J Med 2006; 354:2689-2695.
29. Karagiannidis C, Hense G, Martin C, Epstein M, Rückert B, Mantel PY, et al. Activin A is an acute allergen-responsive cytokine and provides a link to TGF-mediated airway remodeling in asthma. J Allergy Clin Immunol 2006; 117:111-118.
30. Mauad T, Bel EH, Sterk PJ. Asthma therapy and airway remodeling. J Allergy Clin Immunol 2007; 120:997-1009.
31. Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, et al. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 2004; 169:860-867.
32. Yang G,Volk A, PetleyT,Emmell E, Giles-Komar J, ShangX, et al. Anti-IL- 13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004; 28:224-232.
33. Gounni AS,Wellemans V, Yang J, Bellesort F, Kassiri K, Gangloff S, et al. Human airway smooth muscle cells express the high affinity receptor for IgE (Fc-RI): a critical role of Fc-RI in human airway smooth muscle cell function. J Immunol 2005; 175:2613-2621.
34. Hakonarson H, Carter C, Kim C, Grunstein MM. Altered expression and action of the low-affinity IgE receptor Fc-RII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 1999; 104:575-584.
35. Belleau JT, Gandhi RK, McPherson HM, Lew DB. Research upregulation of CD23 (Fc-RII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy 2005; 3:6.
36. Abel M, Vliagoftis H. Mast cell-fibroblast interactions induce matrix metalloproteinase-9 release from fibroblasts: role for IgE-mediated mast cell activation. J Immunol 2008; 180:3543-3550.